Melphalan Aqvida (Melphalan)

Melphalan forms covalent bonds with guanine bases in DNA, creating cross‑links that block replication and transcription. This DNA damage triggers programmed cell death, especially in rapidly dividing tumor cells, providing its antineoplastic effect.

The dose of Melphalan Aqvida is individualized by the prescribing oncologist based on the specific cancer type, patient weight, renal function and treatment protocol. Only a qualified healthcare professional should determine the appropriate regimen.

Melphalan is classified as contraindicated in pregnancy because it can cause fetal harm. It is also not recommended while breastfeeding, as it may be excreted in milk and affect the infant. Women of child‑bearing potential should use effective contraception during treatment.

To request Melphalan Aqvida, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Melphalan shares the DNA‑cross‑linking mechanism common to alkylating agents but differs in its pharmacokinetic profile and approved indications. Compared with agents such as cyclophosphamide, melphalan is often preferred for multiple myeloma and certain solid tumours, though toxicity patterns and dosing schedules vary.

Melphalan Aqvida should be stored at 2‑8 °C, protected from light, and kept in its original container. Do not freeze or shake the solution. Before administration, inspect for particulate matter and ensure aseptic handling according to institutional guidelines.

Melphalan Aqvida is given by intravenous infusion under the supervision of a qualified healthcare professional. The infusion rate and duration are determined by the treatment protocol, and patients are monitored for infusion‑related reactions and vital signs throughout the procedure.

The most serious risks include severe myelosuppression leading to infection, anemia or bleeding, secondary malignancies, and pulmonary toxicity such as interstitial pneumonitis. Prompt recognition and management of these complications are essential during therapy.

Melphalan Aqvida is contraindicated in patients with known hypersensitivity to melphalan or related compounds, in those with severe bone‑marrow failure, and in pregnant or nursing women. Caution is also advised for individuals with significant renal or hepatic impairment.